Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive

NCT03151551 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03151551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03151551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
August 24, 2017
Completion date
September 4, 2019
Enrollment
566 (actual)
Sites
131

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis